Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 16, 2017 16:00 ET | Source: Asterias Biotherapeutics

Asterias Biotherapeutics to Present at Piper Jaffray Healthcare Conference on November 28, 2017

FREMONT, Calif., Nov. 16, 2017 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE MKT:AST), a biotechnology company pioneering the field of regenerative medicine, today announced that Michael...
November 14, 2017 16:10 ET | Source: Asterias Biotherapeutics

Asterias Biotherapeutics Reports Third Quarter Financial Results and Recent Developments

- Continues to execute on key clinical programs and streamline cost structure - - Conference call and webcast today, November 14, at 4:30 p.m. ET - FREMONT, Calif., Nov. 14, 2017 (GLOBE...
November 02, 2017 07:00 ET | Source: Asterias Biotherapeutics

Asterias Biotherapeutics to Report Third Quarter Results on November 14, 2017

FREMONT, Calif., Nov. 02, 2017 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE MKT:AST), a biotechnology company focused on the emerging field of regenerative medicine, today announced that...
October 19, 2017 07:00 ET | Source: Asterias Biotherapeutics

Asterias Biotherapeutics Announces Closing of $10.4 Million Registered Direct Offering

FREMONT, Calif., Oct. 19, 2017 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American:AST), a biotechnology company focused on the field of regenerative medicine, today announced that it...
October 16, 2017 08:30 ET | Source: Asterias Biotherapeutics

Asterias Biotherapeutics Announces $10.4 Million Registered Direct Offering

FREMONT, Calif., Oct. 16, 2017 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American:AST), a biotechnology company focused on the field of regenerative medicine, today announced that it...
October 02, 2017 07:00 ET | Source: Asterias Biotherapeutics

Asterias Announces Two Significant Developments for Spinal Cord Injury Program

67% of Cohort 2 subjects have recovered two or more motor levels on at least one side through 12 months AST-OPC1 receives Regenerative Medicine Advanced Therapy (RMAT) designation from FDA FREMONT,...
September 26, 2017 07:00 ET | Source: Asterias Biotherapeutics

Asterias Receives Regulatory Clearance to Initiate Clinical Study of AST-VAC2 in Subjects with Early and Late Stage Non-Small Cell Lung Cancer

FREMONT, Calif., Sept. 26, 2017 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE MKT:AST), a biotechnology company pioneering the field of regenerative medicine, today announced that the...
September 25, 2017 07:00 ET | Source: Asterias Biotherapeutics

Asterias’ AST-OPC1 Clinical Trial Will Continue as Planned Following Recommendation of Data Monitoring Committee

FREMONT, Calif., Sept. 25, 2017 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American:AST), a biotechnology company pioneering the field of regenerative medicine, today announced that...
September 06, 2017 07:00 ET | Source: Asterias Biotherapeutics

Asterias Biotherapeutics to Present at Upcoming Conferences

FREMONT, Calif., Sept. 06, 2017 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE MKT:AST), a biotechnology company pioneering the field of regenerative medicine, today announced that members...
August 30, 2017 07:00 ET | Source: Asterias Biotherapeutics

Preclinical Data Published in Peer-Reviewed Journal Stem Cells Translational Medicine Provides Scientific Framework for Asterias’ AST-OPC1 for the Treatment of Subacute Cervical Spinal Cord Injury

FREMONT, Calif., Aug. 30, 2017 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE MKT:AST), a biotechnology company pioneering the field of regenerative medicine, today announced the...